Prognostic factors in resected stage I non-small-cell lung cancer: A multivariate analysis of six molecular markers

Journal of Clinical Oncology

Volumn 22, Issue 22, 2004, Pages 4575-4583

  Lu, Charles ^a   Soria, Jean Charles ^a   Tang, Ximing ^a   Xu, Xiao Chun ^a   Wang, Luo ^a   Mao, Li ^a   Lotan, Reuben ^a   Kemp, Bonnie ^a   Bekele, B Nebiyou ^a   Feng, Lei ^a   Hong, Waun K ^a   Khuri, Fadlo R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; DEATH ASSOCIATED PROTEIN KINASE; DIGOXIGENIN; INTERLEUKIN 10; K RAS PROTEIN; MESSENGER RNA; MOLECULAR MARKER; RETINOIC ACID RECEPTOR BETA; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

ALLELE; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVE SITE; GENE EXPRESSION; GENE MUTATION; HUMAN; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METHYLATION; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ADULT; AGED; COHORT ANALYSIS; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 16544386625     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.091     Document Type: Article

References (63)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Travis W, Travis LB, Devesa SS: Lung cancer incidence and survival by histologic type. Cancer 75:191-202, 1995 (suppl 1)
3. Fry W, Phillips JL, Menck HR: Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 86:1867-1876, 1999
4. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997
5. Tseng JE, Kemp BL, Khuri FR, et al: Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 59:4798-1803, 1999
6. Herbst RS, Yano S, Kuniyasu H, et al: Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 6:790-797, 2000
7. Tang X, Khuri FR, Lee JJ, et al: Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92:1511-1516, 2000
8. Khuri FR, Lotan R, Kemp BL, et al: Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 18:2798-2804, 2000
9. Khuri FR, Wu H, Lee JJ, et al: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861-867, 2001
10. Zhou X, Kemp BL, Khuri FR, et al: Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res 6:559-565, 2000
11. Wang L, Soria JC, Kemp BL, et al: HTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 8:2883-2889, 2002
12. Soria JC, Moon C, Kemp BL, et al: Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 9:1785-1791, 2003
13. Pastorino U, Andreola S, Tagliabue E, et al: Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 15:2858-2865, 1997
14. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al: Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications. J Clin Oncol 16:2468-2477, 1998
15. D'Amico TA, Massey M, Herndon JE II, et al: A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736-743, 1999
16. Ahrendt SA, Hu Y, Buta M, et al: p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study. J Natl Cancer Inst 95:961-970, 2003
17. Berard J, Gaboury L, Landers M, et al: Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4-like transgene. EMBO J 13:5570-5580, 1994
18. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90:1609-1620, 1998
19. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761-3764, 1998
20. Wolff H, Saukkonen K, Anttila S, et al: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997-5001, 1998
21. Li M, Song S, Lippman SM, et al: Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene 21:411-418, 2002
22. Hahn WC: Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 21:2034-2043. 2003
23. Hiyama K, Hiyama E, Ishioka S, et al: Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87:895-902, 1995
24. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994
25. Zochbauer-Muller S, Fong KM, Maitra A, et al: 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61:3581-3585, 2001
26. Esteller M, Corn PG, Baylin SB, et al: A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229, 2001
27. Deiss LP, Feinstein E, Berissi H, et al: Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9:15-30, 1995
28. Inbal B, Cohen O, Polak-Charcon S, et al: DAP kinase links the control of apoptosis to metastasis. Nature 390:180-184, 1997
29. Beissert S, Hosoi J, Grabbe S, et al: IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 154:1280-1286, 1995
30. Rohrer JW, Coggin JH Jr: CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 155:5719-5727, 1995
31. Huang S, Ullrich SE, Bar-Eli M: Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19:697-703, 1999
32. Kundu N, Beaty TL, Jackson MJ, et al: Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 88:536-541, 1996
33. Esteller M, Sanchez-Cespedes M, Rosell R, et al: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67-70, 1999
34. Bonfield TL, Konstan MW, Burfeind P, et al: Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 13:257-261, 1995
35. Fujieda S, Lee K, Sunaga H, et al: Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer 85:1439-1445, 1999
36. Kolquist KA, Ellisen LW, Counter CM, et al: Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 19:182-186, 1998
37. Soria JC, Moon C, Wang L, et al: Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 93:1257-1263, 2001
38. Falchetti ML, Pallini R, D'Ambrosio E, et al: In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. Int J Cancer 88:895-901, 2000
39. Xu XC, Ro JY, Lee JS, et al: Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 54:3580-3587, 1994
40. Xu XC, Sozzi G, Lee JS, et al: Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst 89:624-629, 1997
41. Jacobson DR, Mills NE: A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene 9:553-563, 1994
42. Slebos RJ, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565, 1990
43. Kim DH, Nelson HH, Wiencke JK, et al: Promoter methylation of DAP-kinase: Association with advanced stage in non-small cell lung cancer. Oncogene 20:1765-1770, 2001
44. Harden SV, Tokumaru Y, Westra WH, et al: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 9:1370-1375, 2003
45. Gerard CM, Bruyns C, Delvaux A, et al: Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 7:23-31, 1996
46. Stearns ME, Garcia FU, Fudge K, et al: Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 5:711-720, 1999
47. Cervenak L, Morbidelli L, Donati D, et al: Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 96: 2568-2573, 2000
48. Kundu N, Dorsey R, Jackson MJ, et al: Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer 76:713-719, 1998
49. Howell WM, Turner SJ, Bateman AC, et al: IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2:25-31, 2001
50. Sharma S, Stolina M, Lin Y, et al: T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 163:5020-5028, 1999
51. Spagnoli GC, Juretic A, Schultz-Thater E, et al: On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. Cell Immunol 146: 391-405, 1993
52. Huang M, Sharma S, Mao JT, et al: Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157:5512-5520, 1996
53. De Vita F, Orditura M, Galizia G, et al: Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117:365-373, 2000
54. Hatanaka H, Abe Y, Kamiya T, et al: Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11:815-819, 2000
55. Nishimura G, Yanoma S, Mizuno H, et al: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 90:1152-1162, 1999
56. Lonnroth C, Andersson M, Lundholm K: Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 18:929-937, 2001
57. Rouleau J, MacLeod AR, Szyf M: Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway. J Biol Chem 270: 1595-1601, 1995
58. Bigey P, Ramchandani S, Theberge J, et al: Transcriptional regulation of the human DNA methyltransferase (dnmt1) gene. Gene 242:407-418, 2000
59. Pulling LC, Divine KK, Klinge DM, et al: Promoter hypermethylation of the 06-methylguanine-DNA methyltransferase gene: More common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res 63:4842-4848, 2003
60. Moore KW, de Waal Malefyt R, Coffman RL, et al: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765, 2001
61. Molina-Holgado E, Arevalo-Martin A, Ortiz S, et al: Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: Inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10. Neurosci Lett 324:237-241, 2002
62. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
63. Yanagisawa K, Shyr Y, Xu BJ, et al: Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433-439, 2003